department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Acthar · pharmadog

pharmadog
drugs
Acthar

drug

patient view →

corticotropin

Marketedupdated 2mo ago

by Cerium Pharmaceuticals Inc

Approved

community read0 votes

indications

investigational

Rheumatoid ArthritisPsoriasisLupus

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Acthar

generic

corticotropin [INN]

indication

Membranous Glomerulonephritis

phase

marketed

Patent cliff

source: FDA Orange Book

first barrier falls

Jul 18, 2041

~15.0 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (9)

Oct 27, 2043method-of-use (U-3926)US 11975047
Oct 27, 2043method-of-use (U-3915)US 12102662
Oct 27, 2043method-of-use (U-3916)US 12102662
Oct 27, 2043method-of-use (U-3911)US 12233105
Oct 27, 2043formulationUS 12324787
Oct 27, 2043formulationUS 12440542
Jul 18, 2041method-of-use (U-3688)US 11752199
Jul 18, 2041method-of-use (U-3688)US 11752199
Jul 18, 2041method-of-use (U-3688)US 11752199

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Trials studying corticotropin

phase4Treatment of CNS Sarcoidosis With H.P. Acthar Gelcompletedn=4
phase4Use of Acthar in Rheumatoid Arthritis (RA) Related Flarescompletedn=40
phase4Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositiscompletedn=19
phase3The Effects of Acthar on Synovial Inflammation in Rheumatoid Arthritisunknownn=6
N/AOcular Sarcoidosis Open Label Trial of ACTHAR Gelcompletedn=9
N/AACTH Gel Therapy in Rheumatoid Arthritiscompletedn=18